Targeting Breast Cancer with Gene Therapy Using Specific Promoters
Author Information
Author(s): Mariam A Stoff-Khalili, Alexander Stoff, Angel A Rivera, Nilam S Banerjee, Maaike Everts, Scott Young, Gene P Siegal, Dirk F Richter, Minghui Wang, Peter Dall, J Michael Mathis, Zeng B Zhu, David T Curiel
Primary Institution: University of Alabama at Birmingham
Hypothesis
Can tissue-specific promoters enhance the targeting of adenoviral vectors for breast cancer gene therapy?
Conclusion
The CXCR4 promoter is a promising candidate for selective gene therapy in breast cancer due to its high activity in tumor tissues and low activity in normal tissues.
Supporting Evidence
- The CXCR4 promoter showed the highest luciferase activity in breast cancer cell lines and tissue slices.
- Gene expression profiles correlated with promoter activities in both breast cancer cell lines and primary breast cancer cells.
- The CXCR4 promoter had low activity in normal human fibroblasts and liver tissue slices.
Takeaway
This study looked at how to make gene therapy for breast cancer safer by using special markers that only turn on in cancer cells, not in healthy ones.
Methodology
The study used adenoviral vectors with different promoters to evaluate their activity in breast cancer cell lines, primary breast cancer cells, and tissue slices.
Potential Biases
Potential bias in selecting promoters based on previously established links to cancer biology.
Limitations
The study primarily focused on a limited number of promoters and may not encompass all potential candidates for breast cancer gene therapy.
Participant Demographics
Breast cancer samples were obtained from eight patients with varying stages and grades of the disease.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website